PMC:3750932 / 20512-21195 JSONTXT

{"project":"2_test","denotations":[{"id":"23829793-11555513-81675357","span":{"begin":180,"end":182},"obj":"11555513"},{"id":"23829793-18160817-81675358","span":{"begin":183,"end":185},"obj":"18160817"},{"id":"23829793-8432180-81675359","span":{"begin":397,"end":399},"obj":"8432180"},{"id":"23829793-7942794-81675360","span":{"begin":409,"end":411},"obj":"7942794"},{"id":"23829793-16299113-81675361","span":{"begin":573,"end":575},"obj":"16299113"},{"id":"23829793-22451584-81675362","span":{"begin":679,"end":681},"obj":"22451584"},{"id":"T83137","span":{"begin":180,"end":182},"obj":"11555513"},{"id":"T20188","span":{"begin":183,"end":185},"obj":"18160817"},{"id":"T74858","span":{"begin":397,"end":399},"obj":"8432180"},{"id":"T52977","span":{"begin":409,"end":411},"obj":"7942794"},{"id":"T63034","span":{"begin":573,"end":575},"obj":"16299113"},{"id":"T26275","span":{"begin":679,"end":681},"obj":"22451584"}],"text":"Group 5.1 Hematologic disorders \nPH has been reported in chronic myeloproliferative disorders including polycythemia vera, essential thrombocythemia, and chronic myeloid leukemia [79,80]. Several mechanisms may be implicated in PH associated with chronic myeloproliferative disorders including high cardiac output, asplenia, direct obstruction of pulmonary arteries by circulating megakaryocytes [81], CTEPH [82], portal PH, and congestive heart failure. Splenectomy as a result of trauma or as a treatment for hematologic disorders may increase the risk of developing PH [83]. As described above, dasatinib use may be one cause of PAH, particularly in chronic myeloid leukemia [23]."}

{"project":"NEUROSES","denotations":[{"id":"T955","span":{"begin":57,"end":64},"obj":"PATO_0001863"},{"id":"T956","span":{"begin":154,"end":161},"obj":"PATO_0001863"},{"id":"T957","span":{"begin":247,"end":254},"obj":"PATO_0001863"},{"id":"T958","span":{"begin":653,"end":660},"obj":"PATO_0001863"},{"id":"T959","span":{"begin":57,"end":64},"obj":"PATO_0000498"},{"id":"T960","span":{"begin":154,"end":161},"obj":"PATO_0000498"},{"id":"T961","span":{"begin":247,"end":254},"obj":"PATO_0000498"},{"id":"T962","span":{"begin":653,"end":660},"obj":"PATO_0000498"},{"id":"T963","span":{"begin":294,"end":298},"obj":"PATO_0000469"},{"id":"T964","span":{"begin":598,"end":607},"obj":"CHEBI_49375"},{"id":"T965","span":{"begin":598,"end":607},"obj":"CHEBI_70839"},{"id":"T966","span":{"begin":632,"end":635},"obj":"CHEBI_33848"},{"id":"T967","span":{"begin":632,"end":635},"obj":"CHEBI_31204"},{"id":"T968","span":{"begin":632,"end":635},"obj":"CHEBI_104011"},{"id":"T969","span":{"begin":632,"end":635},"obj":"CHEBI_53305"},{"id":"T973","span":{"begin":0,"end":5},"obj":"CHEBI_24433"},{"id":"T975","span":{"begin":154,"end":161},"obj":"PATO_0001863"},{"id":"T976","span":{"begin":247,"end":254},"obj":"PATO_0001863"},{"id":"T977","span":{"begin":653,"end":660},"obj":"PATO_0001863"},{"id":"T978","span":{"begin":154,"end":161},"obj":"PATO_0000498"},{"id":"T979","span":{"begin":247,"end":254},"obj":"PATO_0000498"},{"id":"T980","span":{"begin":653,"end":660},"obj":"PATO_0000498"},{"id":"T981","span":{"begin":294,"end":298},"obj":"PATO_0000469"},{"id":"T982","span":{"begin":598,"end":607},"obj":"CHEBI_49375"},{"id":"T983","span":{"begin":598,"end":607},"obj":"CHEBI_70839"},{"id":"T984","span":{"begin":632,"end":635},"obj":"CHEBI_33848"},{"id":"T985","span":{"begin":632,"end":635},"obj":"CHEBI_31204"},{"id":"T986","span":{"begin":632,"end":635},"obj":"CHEBI_104011"},{"id":"T987","span":{"begin":632,"end":635},"obj":"CHEBI_53305"},{"id":"T1047","span":{"begin":154,"end":178},"obj":"PM2871"},{"id":"T1048","span":{"begin":653,"end":677},"obj":"PM2871"},{"id":"T953","span":{"begin":0,"end":5},"obj":"CHEBI_24433"}],"text":"Group 5.1 Hematologic disorders \nPH has been reported in chronic myeloproliferative disorders including polycythemia vera, essential thrombocythemia, and chronic myeloid leukemia [79,80]. Several mechanisms may be implicated in PH associated with chronic myeloproliferative disorders including high cardiac output, asplenia, direct obstruction of pulmonary arteries by circulating megakaryocytes [81], CTEPH [82], portal PH, and congestive heart failure. Splenectomy as a result of trauma or as a treatment for hematologic disorders may increase the risk of developing PH [83]. As described above, dasatinib use may be one cause of PAH, particularly in chronic myeloid leukemia [23]."}